{"name":"Eli Lilly","slug":"lilly","ticker":"","exchange":"","domain":"lilly.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":36730000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Mounjaro","genericName":"TIRZEPATIDE","slug":"tirzepatide","revenue":15530000000,"yoyGrowth":0,"percentOfTotal":42.3},{"name":"Trulicity","genericName":"DULAGLUTIDE","slug":"dulaglutide","revenue":7200000000,"yoyGrowth":0,"percentOfTotal":19.6},{"name":"Verzenio","genericName":"abemaciclib","slug":"abemaciclib","revenue":3700000000,"yoyGrowth":0,"percentOfTotal":10.1},{"name":"Taltz","genericName":"ixekizumab","slug":"ixekizumab","revenue":2700000000,"yoyGrowth":0,"percentOfTotal":7.4},{"name":"Humalog","genericName":"INSULIN LISPRO","slug":"insulin-lispro","revenue":2200000000,"yoyGrowth":0,"percentOfTotal":6},{"name":"Olumiant","genericName":"baricitinib","slug":"baricitinib","revenue":1200000000,"yoyGrowth":0,"percentOfTotal":3.3},{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","revenue":1000000000,"yoyGrowth":0,"percentOfTotal":2.7},{"name":"Cyramza","genericName":"RAMUCIRUMAB","slug":"ramucirumab","revenue":900000000,"yoyGrowth":0,"percentOfTotal":2.5},{"name":"Omvoh","genericName":"MIRIKIZUMAB","slug":"mirikizumab","revenue":800000000,"yoyGrowth":0,"percentOfTotal":2.2},{"name":"Retevmo","genericName":"SELPERCATINIB","slug":"selpercatinib","revenue":700000000,"yoyGrowth":0,"percentOfTotal":1.9},{"name":"Emgality","genericName":"GALCANEZUMAB","slug":"galcanezumab","revenue":500000000,"yoyGrowth":0,"percentOfTotal":1.4},{"name":"Zyprexa","genericName":"olanzapine","slug":"olanzapine","revenue":300000000,"yoyGrowth":0,"percentOfTotal":0.8}],"timeline":[{"date":"1939-01-01","label":"Eramin first approved","drug":"Eramin","drugSlug":"histamine","type":"approval","sentiment":"positive"},{"date":"1941-01-01","label":"Sulfadiazine first approved","drug":"Sulfadiazine","drugSlug":"sulfadiazine","type":"approval","sentiment":"positive"},{"date":"1950-01-01","label":"Quinidine Gluconate first approved","drug":"Quinidine Gluconate","drugSlug":"quinidine-sulfate","type":"approval","sentiment":"positive"},{"date":"1964-01-01","label":"Dymelor first approved","drug":"Dymelor","drugSlug":"acetohexamide","type":"approval","sentiment":"positive"},{"date":"1970-01-01","label":"Kafocin first approved","drug":"Kafocin","drugSlug":"cefaloglycin","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Cephalotin first approved","drug":"Cephalotin","drugSlug":"cefalotin","type":"approval","sentiment":"positive"},{"date":"1978-01-01","label":"Kefadol first approved","drug":"Kefadol","drugSlug":"cefamandole-nafate","type":"approval","sentiment":"positive"},{"date":"1980-01-01","label":"Cinobac first approved","drug":"Cinobac","drugSlug":"cinoxacin","type":"approval","sentiment":"positive"},{"date":"1982-01-01","label":"Humulin first approved","drug":"Humulin","drugSlug":"insulin","type":"approval","sentiment":"positive"},{"date":"1987-12-29","label":"Prozac first approved","drug":"Prozac","drugSlug":"fluoxetine","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Humalog first approved","drug":"Humalog","drugSlug":"insulin-lispro","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Evista first approved","drug":"Evista","drugSlug":"raloxifene","type":"approval","sentiment":"positive"},{"date":"2002-01-01","label":"Strattera first approved","drug":"Strattera","drugSlug":"atomoxetine","type":"approval","sentiment":"positive"},{"date":"2004-08-03","label":"Cymbalta first approved","drug":"Cymbalta","drugSlug":"duloxetine","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Trulicity first approved","drug":"Trulicity","drugSlug":"dulaglutide","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Cyramza first approved","drug":"Cyramza","drugSlug":"ramucirumab","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Portrazza first approved","drug":"Portrazza","drugSlug":"necitumumab","type":"approval","sentiment":"positive"},{"date":"2016-01-01","label":"Taltz first approved","drug":"Taltz","drugSlug":"ixekizumab","type":"approval","sentiment":"positive"},{"date":"2016-01-01","label":"Lartruvo first approved","drug":"Lartruvo","drugSlug":"olaratumab","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Verzenio first approved","drug":"Verzenio","drugSlug":"abemaciclib","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Olumiant first approved","drug":"Olumiant","drugSlug":"baricitinib","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Emgality first approved","drug":"Emgality","drugSlug":"galcanezumab","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Reyvow first approved","drug":"Reyvow","drugSlug":"lasmiditan","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Retevmo first approved","drug":"Retevmo","drugSlug":"selpercatinib","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Ly-Cov016 first approved","drug":"Ly-Cov016","drugSlug":"etesevimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Ly-Cov555 first approved","drug":"Ly-Cov555","drugSlug":"bamlanivimab","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Mounjaro first approved","drug":"Mounjaro","drugSlug":"tirzepatide","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Inluriyo first approved","drug":"Inluriyo","drugSlug":"imlunestrant","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Ebglyss first approved","drug":"Ebglyss","drugSlug":"lebrikizumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-08-31","label":"Cialis Phase 3 readout (Prostate Carcinoma, Erectile Function)","drug":"Cialis","drugSlug":"tadalafil","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-01","label":"Verzenio PHASE3 readout","drug":"Verzenio","drugSlug":"abemaciclib","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-12-01","label":"Cyramza PHASE3 readout","drug":"Cyramza","drugSlug":"ramucirumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-01","label":"Retevmo PHASE1,PHASE2 readout","drug":"Retevmo","drugSlug":"selpercatinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-08-01","label":"Inluriyo PHASE3 readout","drug":"Inluriyo","drugSlug":"imlunestrant","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-01","label":"Verzenio PHASE3 readout","drug":"Verzenio","drugSlug":"abemaciclib","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-02-29","label":"Cialis Phase 3 readout (Hypertension, Pulmonary)","drug":"Cialis","drugSlug":"tadalafil","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-30","label":"Zyprexa Phase 3 readout (Standard Quadruple Antiemetic Therapy, Electroacupuncture)","drug":"Zyprexa","drugSlug":"olanzapine","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-05-01","label":"Verzenio PHASE3 readout","drug":"Verzenio","drugSlug":"abemaciclib","type":"phase3_readout","sentiment":"neutral"},{"date":"2038-10-10","label":"Retevmo patent expiry (Compound)","drug":"Retevmo","drugSlug":"selpercatinib","type":"patent_expiry","sentiment":"negative"},{"date":"2038-10-10","label":"Retevmo patent expiry (Formulation)","drug":"Retevmo","drugSlug":"selpercatinib","type":"patent_expiry","sentiment":"negative"},{"date":"2038-12-24","label":"Cialis patent expiry (Formulation)","drug":"Cialis","drugSlug":"tadalafil","type":"patent_expiry","sentiment":"negative"},{"date":"2038-12-24","label":"Cialis patent expiry (Formulation)","drug":"Cialis","drugSlug":"tadalafil","type":"patent_expiry","sentiment":"negative"},{"date":"2038-12-24","label":"Cialis patent expiry (Formulation)","drug":"Cialis","drugSlug":"tadalafil","type":"patent_expiry","sentiment":"negative"},{"date":"2038-12-24","label":"Cialis patent expiry (Formulation)","drug":"Cialis","drugSlug":"tadalafil","type":"patent_expiry","sentiment":"negative"},{"date":"2039-04-10","label":"Retevmo patent expiry (Compound)","drug":"Retevmo","drugSlug":"selpercatinib","type":"patent_expiry","sentiment":"negative"},{"date":"2039-04-10","label":"Retevmo patent expiry (Compound)","drug":"Retevmo","drugSlug":"selpercatinib","type":"patent_expiry","sentiment":"negative"},{"date":"2039-06-14","label":"Mounjaro patent expiry (Method of Use)","drug":"Mounjaro","drugSlug":"tirzepatide","type":"patent_expiry","sentiment":"negative"},{"date":"2039-07-22","label":"Mounjaro patent expiry (Method of Use)","drug":"Mounjaro","drugSlug":"tirzepatide","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":24930000000,"percentOfTotal":67.9,"drugCount":65,"colorKey":"oncology","drugs":[{"name":"Mounjaro","genericName":"TIRZEPATIDE","slug":"tirzepatide","indication":"Diabetes mellitus type 2","status":"marketed","revenue":15530000000},{"name":"Trulicity","genericName":"DULAGLUTIDE","slug":"dulaglutide","indication":"Diabetes mellitus type 2","status":"marketed","revenue":7200000000},{"name":"Humalog","genericName":"INSULIN LISPRO","slug":"insulin-lispro","indication":"Diabetes mellitus type 1","status":"marketed","revenue":2200000000},{"name":"Humulin","genericName":"insulin","slug":"insulin","indication":"Diabetes mellitus type 1","status":"marketed"},{"name":"Dymelor","genericName":"ACETOHEXAMIDE","slug":"acetohexamide","indication":"Diabetes mellitus type 2","status":"marketed"},{"name":"Glucagon IM","genericName":"Glucagon IM","slug":"glucagon-im","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Glucagon Nasal Powder","genericName":"Glucagon Nasal Powder","slug":"glucagon-nasal-powder","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Human Insulin Inhalation Powder","genericName":"Human Insulin Inhalation Powder","slug":"human-insulin-inhalation-powder","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Huminsulin Regular","genericName":"Huminsulin Regular","slug":"huminsulin-regular","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro (U100)","genericName":"Insulin Lispro (U100)","slug":"insulin-lispro-u100","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Lispro Mix50","genericName":"Insulin Lispro Mix50","slug":"insulin-lispro-mix50","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro-aabc","genericName":"Insulin Lispro-aabc","slug":"insulin-lispro-aabc","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro 2 day reservoir in-use","genericName":"Insulin lispro 2 day reservoir in-use","slug":"insulin-lispro-2-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY2963016","genericName":"LY2963016","slug":"ly2963016","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY3537982","genericName":"LY3537982","slug":"ly3537982","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY3650150","genericName":"LY3650150","slug":"ly3650150","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Lispro Mixture Therapy","genericName":"Lispro Mixture Therapy","slug":"lispro-mixture-therapy","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"AM0010","genericName":"AM0010","slug":"am0010","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Analog or Human Insulin","genericName":"Analog or Human Insulin","slug":"analog-or-human-insulin","indication":"Type 1 diabetes","status":"phase_2"},{"name":"Basal Insulin Analog","genericName":"Basal Insulin Analog","slug":"basal-insulin-analog","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Biguanide (BG)","genericName":"Biguanide (BG)","slug":"biguanide-bg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Biguanides (BG)","genericName":"Biguanides (BG)","slug":"biguanides-bg","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Exenatide once weekly (QW)","genericName":"Exenatide once weekly (QW)","slug":"exenatide-once-weekly-qw","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Exenatide twice daily (BID)","genericName":"Exenatide twice daily (BID)","slug":"exenatide-twice-daily-bid","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Glucagon Hydrochloride Solution","genericName":"Glucagon Hydrochloride Solution","slug":"glucagon-hydrochloride-solution","indication":"Severe hypoglycemia in patients with diabetes mellitus","status":"phase_3"},{"name":"Humalog Mix 50","genericName":"Humalog Mix 50","slug":"humalog-mix-50","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Human Insulin Mix 50:50","genericName":"Human Insulin Mix 50:50","slug":"human-insulin-mix-50-50","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Human Regular U-500 Insulin","genericName":"Human Regular U-500 Insulin","slug":"human-regular-u-500-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Human insulin 30/70","genericName":"Human insulin 30/70","slug":"human-insulin-30-70","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Injectable insulin","genericName":"Injectable insulin","slug":"injectable-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Analog Mid Mixture","genericName":"Insulin Analog Mid Mixture","slug":"insulin-analog-mid-mixture","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Aspart 6 Day (6D)","genericName":"Insulin Aspart 6 Day (6D)","slug":"insulin-aspart-6-day-6d","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Biphasic Aspart 30/70","genericName":"Insulin Biphasic Aspart 30/70","slug":"insulin-biphasic-aspart-30-70","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro 6 Day (6D)","genericName":"Insulin Lispro 6 Day (6D)","slug":"insulin-lispro-6-day-6d","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin Lispro Mix25","genericName":"Insulin Lispro Mix25","slug":"insulin-lispro-mix25","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro Premix","genericName":"Insulin Lispro Premix","slug":"insulin-lispro-premix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro Protamine Suspension","genericName":"Insulin Lispro Protamine Suspension","slug":"insulin-lispro-protamine-suspension","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin Lispro low mixture","genericName":"Insulin Lispro low mixture","slug":"insulin-lispro-low-mixture","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin aspart 6 day reservoir in-use","genericName":"Insulin aspart 6 day reservoir in-use","slug":"insulin-aspart-6-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin lispro (Humalog)","genericName":"Insulin lispro (Humalog)","slug":"insulin-lispro-humalog","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro 6 day reservoir in-use","genericName":"Insulin lispro 6 day reservoir in-use","slug":"insulin-lispro-6-day-reservoir-in-use","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin lispro A","genericName":"Insulin lispro A","slug":"insulin-lispro-a","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro low mix","genericName":"Insulin lispro low mix","slug":"insulin-lispro-low-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin lispro mix 25","genericName":"Insulin lispro mix 25","slug":"insulin-lispro-mix-25","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Intramuscular Glucagon","genericName":"Intramuscular Glucagon","slug":"intramuscular-glucagon","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"LY2189265","genericName":"LY2189265","slug":"ly2189265","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY2605541","genericName":"LY2605541","slug":"ly2605541","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"LY3537031","genericName":"LY3537031","slug":"ly3537031","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY3819253","genericName":"LY3819253","slug":"ly3819253","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY900003","genericName":"LY900003","slug":"ly900003","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY900014","genericName":"LY900014","slug":"ly900014","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Lispro Low Mix","genericName":"Lispro Low Mix","slug":"lispro-low-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro Mid Mix","genericName":"Lispro Mid Mix","slug":"lispro-mid-mix","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro Mix 50/50","genericName":"Lispro Mix 50/50","slug":"lispro-mix-50-50","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Lispro mix 75/25","genericName":"Lispro mix 75/25","slug":"lispro-mix-75-25","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Nasal Glucagon (NG)","genericName":"Nasal Glucagon (NG)","slug":"nasal-glucagon-ng","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Neutral protamine hagedorn insulin","genericName":"Neutral protamine hagedorn insulin","slug":"neutral-protamine-hagedorn-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"OAMs","genericName":"OAMs","slug":"oams","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Oral antihyperglycemics","genericName":"Oral antihyperglycemics","slug":"oral-antihyperglycemics","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Prandial Insulin Lispro","genericName":"Prandial Insulin Lispro","slug":"prandial-insulin-lispro","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Standard therapy for INCS","genericName":"Standard therapy for INCS","slug":"standard-therapy-for-incs","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Ultra-Rapid Lispro","genericName":"Ultra-Rapid Lispro","slug":"ultra-rapid-lispro","indication":"Treatment of diabetes mellitus","status":"phase_3"},{"name":"injected insulin","genericName":"injected insulin","slug":"injected-insulin","indication":"Type 1 diabetes","status":"phase_3"},{"name":"insulin lispro LM","genericName":"insulin lispro LM","slug":"insulin-lispro-lm","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"insulin lispro MM","genericName":"insulin lispro MM","slug":"insulin-lispro-mm","indication":"Type 1 diabetes mellitus","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":5300000000,"percentOfTotal":14.4,"drugCount":26,"colorKey":"immunology","drugs":[{"name":"Verzenio","genericName":"abemaciclib","slug":"abemaciclib","indication":"Hormone receptor positive malignant neoplasm of breast","status":"marketed","revenue":3700000000},{"name":"Cyramza","genericName":"RAMUCIRUMAB","slug":"ramucirumab","indication":"Adenocarcinoma of stomach","status":"marketed","revenue":900000000},{"name":"Retevmo","genericName":"SELPERCATINIB","slug":"selpercatinib","indication":"Advanced RET fusion-positive non-small cell lung cancer","status":"marketed","revenue":700000000},{"name":"Inluriyo","genericName":"IMLUNESTRANT","slug":"imlunestrant","indication":"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","status":"marketed"},{"name":"ALIMTA plus Epirubicin","genericName":"ALIMTA plus Epirubicin","slug":"alimta-plus-epirubicin","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"Any platinum-based doublet chemotherapy","genericName":"Any platinum-based doublet chemotherapy","slug":"any-platinum-based-doublet-chemotherapy","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"BEC2 Vaccine","genericName":"BEC2 Vaccine","slug":"bec2-vaccine","indication":"Small cell lung cancer (SCLC)","status":"phase_3"},{"name":"Bevacizumab (Bev)","genericName":"Bevacizumab (Bev)","slug":"bevacizumab-bev","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"marketed"},{"name":"Docetaxel (Taxane)","genericName":"Docetaxel (Taxane)","slug":"docetaxel-taxane","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"Eramin","genericName":"HISTAMINE","slug":"histamine","indication":"Acute myeloid leukemia, disease","status":"marketed"},{"name":"Erbitux (Cetuximab)","genericName":"Erbitux (Cetuximab)","slug":"erbitux-cetuximab","indication":"Metastatic colorectal cancer (KRAS wild-type)","status":"phase_3"},{"name":"Evista","genericName":"RALOXIFENE","slug":"raloxifene","indication":"Postmenopausal osteoporosis","status":"marketed"},{"name":"LOXO-305","genericName":"LOXO-305","slug":"loxo-305","indication":"Relapsed or refractory mantle cell lymphoma","status":"phase_2"},{"name":"LY3832479","genericName":"LY3832479","slug":"ly3832479","indication":"Metastatic non-small cell lung cancer","status":"phase_2"},{"name":"LY3838915","genericName":"LY3838915","slug":"ly3838915","indication":"Relapsed or refractory non-Hodgkin lymphoma","status":"phase_2"},{"name":"LY4065967","genericName":"LY4065967","slug":"ly4065967","indication":"FGFR-altered solid tumors (Phase 2 development)","status":"phase_2"},{"name":"Lartruvo","genericName":"OLARATUMAB","slug":"olaratumab","indication":"Sarcoma of soft tissue","status":"marketed"},{"name":"Metholone","genericName":"drostanolone propionate","slug":"drostanolone-propionate","indication":"Malignant neoplasm of breast","status":"marketed"},{"name":"Paclitaxel (Taxane)","genericName":"Paclitaxel (Taxane)","slug":"paclitaxel-taxane","indication":"Metastatic carcinoma of the ovary","status":"phase_3"},{"name":"Portrazza","genericName":"NECITUMUMAB","slug":"necitumumab","indication":"Non-small cell lung cancer","status":"marketed"},{"name":"Ramucirumab (IMC-1211B) DP","genericName":"Ramucirumab (IMC-1211B) DP","slug":"ramucirumab-imc-1211b-dp","indication":"Metastatic non-small cell lung cancer (in combination with docetaxel)","status":"phase_3"},{"name":"Ramucirumab DP (IMC-1121B)","genericName":"Ramucirumab DP (IMC-1121B)","slug":"ramucirumab-dp-imc-1121b","indication":"Non-small cell lung cancer, gastric cancer, and other solid tumors","status":"phase_3"},{"name":"Remternetug (IV)","genericName":"Remternetug (IV)","slug":"remternetug-iv","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Remternetug (SC)","genericName":"Remternetug (SC)","slug":"remternetug-sc","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Sofetabart Mipitecan","genericName":"Sofetabart Mipitecan","slug":"sofetabart-mipitecan","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"ramucirumab (IMC-1121B)","genericName":"ramucirumab (IMC-1121B)","slug":"ramucirumab-imc-1121b","indication":"Metastatic gastric cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":4700000000,"percentOfTotal":12.8,"drugCount":11,"colorKey":"cardiovascular","drugs":[{"name":"Taltz","genericName":"ixekizumab","slug":"ixekizumab","indication":"Ankylosing spondylitis","status":"marketed","revenue":2700000000},{"name":"Olumiant","genericName":"baricitinib","slug":"baricitinib","indication":"Alopecia areata","status":"marketed","revenue":1200000000},{"name":"Omvoh","genericName":"MIRIKIZUMAB","slug":"mirikizumab","indication":"Ulcerative Colitis","status":"marketed","revenue":800000000},{"name":"Commercially-available Aspirin","genericName":"Commercially-available Aspirin","slug":"commercially-available-aspirin","indication":"Acute myocardial infarction","status":"phase_3"},{"name":"Ixekizumab Auto-Injector","genericName":"Ixekizumab Auto-Injector","slug":"ixekizumab-auto-injector","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Ixekizumab Prefilled Syringe","genericName":"Ixekizumab Prefilled Syringe","slug":"ixekizumab-prefilled-syringe","indication":"Moderate to severe plaque psoriasis","status":"marketed"},{"name":"OMVOH","genericName":"MIRIKIZUMAB-MRKZ","slug":"mirikizumab-mrkz","indication":"Moderately to severely active ulcerative colitis","status":"marketed"},{"name":"Sulfadiazine","genericName":"SULFADIAZINE","slug":"sulfadiazine","indication":"Burn Wound Infections","status":"marketed"},{"name":"Topical Corticosteroid (TCS)","genericName":"Topical Corticosteroid (TCS)","slug":"topical-corticosteroid-tcs","indication":"Eczema","status":"phase_3"},{"name":"Triamcinolone (Optional)","genericName":"Triamcinolone (Optional)","slug":"triamcinolone-optional","indication":"Inflammatory and allergic conditions (dermatitis, eczema, psoriasis)","status":"marketed"},{"name":"cDMARD","genericName":"cDMARD","slug":"cdmard","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":1800000000,"percentOfTotal":4.9,"drugCount":18,"colorKey":"neuroscience","drugs":[{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","indication":"Bipolar affective disorder, current episode depression","status":"marketed","revenue":1000000000},{"name":"Emgality","genericName":"GALCANEZUMAB","slug":"galcanezumab","indication":"Preventive treatment of migraine","status":"marketed","revenue":500000000},{"name":"Zyprexa","genericName":"olanzapine","slug":"olanzapine","indication":"Agitation associated with Bipolar Mania","status":"marketed","revenue":300000000},{"name":"Cymbalta","genericName":"duloxetine","slug":"duloxetine","indication":"Chronic Musculoskeletal Pain","status":"marketed"},{"name":"LY2216684","genericName":"LY2216684","slug":"ly2216684","indication":"Major depressive disorder","status":"phase_3"},{"name":"LY450139","genericName":"LY450139","slug":"ly450139","indication":"Alzheimer's disease (mild cognitive impairment and mild dementia stages)","status":"phase_3"},{"name":"Duloxetine (DLX)","genericName":"Duloxetine (DLX)","slug":"duloxetine-dlx","indication":"Major depressive disorder","status":"phase_3"},{"name":"Duloxetine Hydrochloride (HCI)","genericName":"Duloxetine Hydrochloride (HCI)","slug":"duloxetine-hydrochloride-hci","indication":"Major depressive disorder","status":"phase_3"},{"name":"Intramuscular Olanzapine Depot","genericName":"Intramuscular Olanzapine Depot","slug":"intramuscular-olanzapine-depot","indication":"Schizophrenia maintenance treatment","status":"phase_3"},{"name":"LY2216684 (edivoxetine)","genericName":"LY2216684 (edivoxetine)","slug":"ly2216684-edivoxetine","indication":"Attention-deficit/hyperactivity disorder (ADHD)","status":"phase_3"},{"name":"Oral Olanzapine","genericName":"Oral Olanzapine","slug":"oral-olanzapine","indication":"Schizophrenia","status":"marketed"},{"name":"Osmotic-release oral system methylphenidate","genericName":"Osmotic-release oral system methylphenidate","slug":"osmotic-release-oral-system-methylphenidate","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults","status":"marketed"},{"name":"Other standard therapy for ADHD","genericName":"Other standard therapy for ADHD","slug":"other-standard-therapy-for-adhd","indication":"Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"phase_3"},{"name":"Pagitane","genericName":"CYCRIMINE","slug":"cycrimine","indication":"Parkinson's disease","status":"marketed"},{"name":"Rapid Acting Intramuscular Olanzapine","genericName":"Rapid Acting Intramuscular Olanzapine","slug":"rapid-acting-intramuscular-olanzapine","indication":"Treatment of schizophrenia","status":"phase_3"},{"name":"Reyvow","genericName":"LASMIDITAN","slug":"lasmiditan","indication":"Migraine","status":"marketed"},{"name":"olanzapine pamoate depot","genericName":"olanzapine pamoate depot","slug":"olanzapine-pamoate-depot","indication":"Schizophrenia (maintenance treatment)","status":"phase_3"},{"name":"olanzapine therapy","genericName":"olanzapine therapy","slug":"olanzapine-therapy","indication":"Schizophrenia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":76,"colorKey":"infectious","drugs":[{"name":"Glargine","genericName":"Glargine","slug":"glargine","indication":"Other","status":"marketed"},{"name":"Strattera","genericName":"ATOMOXETINE","slug":"atomoxetine","indication":"Attention deficit hyperactivity disorder","status":"marketed"},{"name":"1121B","genericName":"1121B","slug":"1121b","indication":"Other","status":"phase_1"},{"name":"Decabid","genericName":"INDECAINIDE","slug":"indecainide","indication":"Other","status":"marketed"},{"name":"Glargine Basal-Bolus Therapy","genericName":"Glargine Basal-Bolus Therapy","slug":"glargine-basal-bolus-therapy","indication":"Other","status":"marketed"},{"name":"LY3819469","genericName":"LY3819469","slug":"ly3819469","indication":"Other","status":"phase_2"},{"name":"LY3848575","genericName":"LY3848575","slug":"ly3848575","indication":"Other","status":"phase_2"},{"name":"LY3962673","genericName":"LY3962673","slug":"ly3962673","indication":"Other","status":"phase_1"},{"name":"LY4100511","genericName":"LY4100511","slug":"ly4100511","indication":"Other","status":"phase_2"},{"name":"LY4175408","genericName":"LY4175408","slug":"ly4175408","indication":"Other","status":"phase_1"},{"name":"LY451395","genericName":"LY451395","slug":"ly451395","indication":"Other","status":"phase_2"},{"name":"Metocurine","genericName":"dimethyltubocurarinium","slug":"dimethyltubocurarinium","indication":"Muscle relaxation, function","status":"marketed"},{"name":"Placebo (PLA)","genericName":"Placebo (PLA)","slug":"placebo-pla","indication":"Control arm in randomized controlled trials across multiple therapeutic areas","status":"marketed"},{"name":"aldrenodate","genericName":"aldrenodate","slug":"aldrenodate","indication":"Other","status":"marketed"},{"name":"zuclopentixol","genericName":"zuclopentixol","slug":"zuclopentixol","indication":"Other","status":"marketed"},{"name":"Alfarol 1.0 µg","genericName":"Alfarol 1.0 µg","slug":"alfarol-1-0-g","indication":"Hypocalcemia and secondary hyperparathyroidism in chronic kidney disease","status":"marketed"},{"name":"Anastrozole, Exemestane, or Letrozole","genericName":"Anastrozole, Exemestane, or Letrozole","slug":"anastrozole-exemestane-or-letrozole","indication":"Other","status":"phase_1"},{"name":"Axiron","genericName":"Axiron","slug":"axiron","indication":"Other","status":"marketed"},{"name":"Background Chemotherapy","genericName":"Background Chemotherapy","slug":"background-chemotherapy","indication":"Other","status":"phase_2"},{"name":"Bortezomib IV","genericName":"Bortezomib IV","slug":"bortezomib-iv","indication":"Other","status":"phase_1"},{"name":"Brenipatide","genericName":"Brenipatide","slug":"brenipatide","indication":"Other","status":"phase_3"},{"name":"Dicurin Procaine","genericName":"MERETHOXYLLINE PROCAINE","slug":"merethoxylline-procaine","indication":"Other","status":"marketed"},{"name":"Digicor","genericName":"DIGITOXIN","slug":"digitoxin","indication":"Other","status":"marketed"},{"name":"Duloxetine hydrochloride - 60 mg","genericName":"Duloxetine hydrochloride - 60 mg","slug":"duloxetine-hydrochloride-60-mg","indication":"Other","status":"marketed"},{"name":"EBGLYSS","genericName":"LEBRIKIZUMAB-LBKZ","slug":"lebrikizumab-lbkz","indication":"Other","status":"marketed"},{"name":"Glinides","genericName":"Glinides","slug":"glinides","indication":"Other","status":"phase_3"},{"name":"Human insulin isophane suspension","genericName":"Human insulin isophane suspension","slug":"human-insulin-isophane-suspension","indication":"Other","status":"marketed"},{"name":"IMC-1121B","genericName":"IMC-1121B","slug":"imc-1121b","indication":"Other","status":"phase_2"},{"name":"IMC-18F1","genericName":"IMC-18F1","slug":"imc-18f1","indication":"Other","status":"phase_2"},{"name":"Insulin lispro B","genericName":"Insulin lispro B","slug":"insulin-lispro-b","indication":"Other","status":"phase_1"},{"name":"KISUNLA","genericName":"DONANEMAB-AZBT","slug":"donanemab-azbt","indication":"Other","status":"marketed"},{"name":"Kafocin","genericName":"cefaloglycin","slug":"cefaloglycin","indication":"Other","status":"marketed"},{"name":"Kappadione","genericName":"MENADIOL SODIUM DIPHOSPHATE","slug":"menadiol-sodium-diphosphate","indication":"Hemorrhage","status":"marketed"},{"name":"Kefadol","genericName":"CEFAMANDOLE NAFATE","slug":"cefamandole-nafate","indication":"Other","status":"marketed"},{"name":"LOXO-783","genericName":"LOXO-783","slug":"loxo-783","indication":"Other","status":"phase_1"},{"name":"LY2062430","genericName":"LY2062430","slug":"ly2062430","indication":"Huntington's disease","status":"phase_3"},{"name":"LY2189265 and Lifestyle Measures","genericName":"LY2189265 and Lifestyle Measures","slug":"ly2189265-and-lifestyle-measures","indication":"Other","status":"phase_2"},{"name":"LY2196044","genericName":"LY2196044","slug":"ly2196044","indication":"Other","status":"phase_2"},{"name":"LY2422347","genericName":"LY2422347","slug":"ly2422347","indication":"Other","status":"phase_2"},{"name":"LY2541546 - SC","genericName":"LY2541546 - SC","slug":"ly2541546-sc","indication":"Other","status":"phase_1"},{"name":"LY2584702 Reference Formulation","genericName":"LY2584702 Reference Formulation","slug":"ly2584702-reference-formulation","indication":"Other","status":"phase_1"},{"name":"LY2603618","genericName":"LY2603618","slug":"ly2603618","indication":"Other","status":"phase_2"},{"name":"LY2787106","genericName":"LY2787106","slug":"ly2787106","indication":"Other","status":"phase_1"},{"name":"LY3016859","genericName":"LY3016859","slug":"ly3016859","indication":"Other","status":"phase_2"},{"name":"LY3457263","genericName":"LY3457263","slug":"ly3457263","indication":"Other","status":"phase_2"},{"name":"LY3502970","genericName":"LY3502970","slug":"ly3502970","indication":"Other","status":"phase_2"},{"name":"LY3839840","genericName":"LY3839840","slug":"ly3839840","indication":"Other","status":"phase_1"},{"name":"LY3857210","genericName":"LY3857210","slug":"ly3857210","indication":"Other","status":"phase_2"},{"name":"LY4057996 IV","genericName":"LY4057996 IV","slug":"ly4057996-iv","indication":"Other","status":"phase_1"},{"name":"LY573636-sodium","genericName":"LY573636-sodium","slug":"ly573636-sodium","indication":"Other","status":"phase_2"},{"name":"Lispro","genericName":"Lispro","slug":"lispro","indication":"Other","status":"marketed"},{"name":"Lispro Prandial Insulin","genericName":"Lispro Prandial Insulin","slug":"lispro-prandial-insulin","indication":"Other","status":"phase_1"},{"name":"Menadion","genericName":"MENADIONE","slug":"menadione","indication":"Other","status":"marketed"},{"name":"Moxam","genericName":"latamoxef","slug":"latamoxef","indication":"Other","status":"marketed"},{"name":"PPAR alpha","genericName":"PPAR alpha","slug":"ppar-alpha","indication":"Other","status":"phase_2"},{"name":"Pemetrexed Phase 2","genericName":"Pemetrexed Phase 2","slug":"pemetrexed-phase-2","indication":"Other","status":"phase_2"},{"name":"Placebo (for Ramucirumab)","genericName":"Placebo (for Ramucirumab)","slug":"placebo-for-ramucirumab","indication":"Other","status":"phase_3"},{"name":"Placebo as Capsules","genericName":"Placebo as Capsules","slug":"placebo-as-capsules","indication":"Control arm in phase 3 clinical trials (specific indication unknown)","status":"phase_3"},{"name":"Placebo every 2 weeks","genericName":"Placebo every 2 weeks","slug":"placebo-every-2-weeks","indication":"Other","status":"phase_3"},{"name":"Placebo every 4 weeks","genericName":"Placebo every 4 weeks","slug":"placebo-every-4-weeks","indication":"Other","status":"phase_3"},{"name":"Placebo for Abemaciclib","genericName":"Placebo for Abemaciclib","slug":"placebo-for-abemaciclib","indication":"Control arm in phase 3 clinical trials of abemaciclib","status":"phase_3"},{"name":"Placebo-Oral","genericName":"Placebo-Oral","slug":"placebo-oral","indication":"Clinical trial control comparator (not a therapeutic indication)","status":"marketed"},{"name":"Platinol","genericName":"Platinol","slug":"platinol","indication":"Other","status":"phase_1"},{"name":"Raloxifene HCL","genericName":"Raloxifene HCL","slug":"raloxifene-hcl","indication":"Other","status":"marketed"},{"name":"Ramucirumab - SC","genericName":"Ramucirumab - SC","slug":"ramucirumab-sc","indication":"Other","status":"phase_1"},{"name":"Ramucirumab DP","genericName":"Ramucirumab DP","slug":"ramucirumab-dp","indication":"Other","status":"phase_2"},{"name":"Salmon Calcitonin","genericName":"Salmon Calcitonin","slug":"salmon-calcitonin","indication":"Paget's disease of bone","status":"marketed"},{"name":"Somatropin (rDNA origin)","genericName":"Somatropin (rDNA origin)","slug":"somatropin-rdna-origin","indication":"Growth hormone deficiency in children","status":"phase_3"},{"name":"Stimulants","genericName":"Stimulants","slug":"stimulants","indication":"Other","status":"phase_2"},{"name":"Tadalafil 5 mg","genericName":"Tadalafil 5 mg","slug":"tadalafil-5-mg","indication":"Other","status":"marketed"},{"name":"Vepugratinib","genericName":"Vepugratinib","slug":"vepugratinib","indication":"Other","status":"phase_3"},{"name":"[^13C4D3^15N]-baricitinib","genericName":"[^13C4D3^15N]-baricitinib","slug":"13c4d3-15n-baricitinib","indication":"Other","status":"phase_1"},{"name":"antiresorptives","genericName":"antiresorptives","slug":"antiresorptives","indication":"Other","status":"phase_2"},{"name":"placebo (tadalafil)","genericName":"placebo (tadalafil)","slug":"placebo-tadalafil","indication":"Erectile dysfunction","status":"phase_3"},{"name":"premeal insulin lispro mixtures","genericName":"premeal insulin lispro mixtures","slug":"premeal-insulin-lispro-mixtures","indication":"Other","status":"marketed"},{"name":"raloxifene HCI and alendronate Na","genericName":"raloxifene HCI and alendronate Na","slug":"raloxifene-hci-and-alendronate-na","indication":"Postmenopausal osteoporosis prevention and treatment","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"respiratory","drugs":[{"name":"Alpha1 Blocker","genericName":"Alpha1 Blocker","slug":"alpha1-blocker","indication":"Hypertension","status":"marketed"},{"name":"Cialis","genericName":"tadalafil","slug":"tadalafil","indication":"Benign prostatic hyperplasia","status":"marketed"},{"name":"ADP receptor inhibitors","genericName":"ADP receptor inhibitors","slug":"adp-receptor-inhibitors","indication":"Acute coronary syndrome","status":"phase_2"},{"name":"Dulaglutide Pen","genericName":"Dulaglutide Pen","slug":"dulaglutide-pen","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"ERA as specific PAH treatment","genericName":"ERA as specific PAH treatment","slug":"era-as-specific-pah-treatment","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"LY353381","genericName":"LY353381","slug":"ly353381","indication":"Osteoporosis prevention and treatment in postmenopausal women","status":"phase_3"},{"name":"Quinidine Gluconate","genericName":"QUINIDINE SULFATE","slug":"quinidine-sulfate","indication":"Atrial fibrillation","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"rare","drugs":[{"name":"Cinobac","genericName":"CINOXACIN","slug":"cinoxacin","indication":"Urinary tract infectious disease","status":"marketed"},{"name":"Cephalotin","genericName":"cefalotin","slug":"cefalotin","indication":"Bacterial infection due to Klebsiella pneumoniae","status":"marketed"},{"name":"Ly-Cov016","genericName":"ETESEVIMAB","slug":"etesevimab","indication":"COVID-19","status":"marketed"},{"name":"Ly-Cov555","genericName":"BAMLANIVIMAB","slug":"bamlanivimab","indication":"COVID-19","status":"discontinued"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Ebglyss","genericName":"LEBRIKIZUMAB","slug":"lebrikizumab","indication":"Moderate-to-severe atopic dermatitis","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"Lebrikizumab Pen","genericName":"Lebrikizumab Pen","slug":"lebrikizumab-pen","indication":"Moderate-to-severe atopic dermatitis","status":"phase_3"}]}],"pipeline":[{"name":"Mounjaro","genericName":"TIRZEPATIDE","slug":"tirzepatide","phase":"marketed","mechanism":"Tirzepatide is a dual GIP and GLP-1 receptor agonist with C20 fatty diacid for albumin binding.","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Trulicity","genericName":"DULAGLUTIDE","slug":"dulaglutide","phase":"marketed","mechanism":"Dulaglutide activates GLP-1 receptors, increasing insulin release and decreasing glucagon secretion and gastric emptying.","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Verzenio","genericName":"abemaciclib","slug":"abemaciclib","phase":"marketed","mechanism":"Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression.","indications":["Hormone receptor positive malignant neoplasm of breast","Human epidermal growth factor 2 negative carcinoma of breast"],"catalyst":""},{"name":"Taltz","genericName":"ixekizumab","slug":"ixekizumab","phase":"marketed","mechanism":"Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor.","indications":["Ankylosing spondylitis","Erythrodermic psoriasis","Non-radiographic axial spondyloarthritis","Plaque psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"Humalog","genericName":"INSULIN LISPRO","slug":"insulin-lispro","phase":"marketed","mechanism":"Humalog works by mimicking the natural hormone insulin to help cells absorb glucose from the bloodstream.","indications":["Diabetes mellitus type 1","Diabetes mellitus type 2"],"catalyst":""},{"name":"Olumiant","genericName":"baricitinib","slug":"baricitinib","phase":"marketed","mechanism":"Tyrosine-protein kinase JAK2","indications":["Alopecia areata","Atopic dermatitis","Pneumonia caused by Severe acute respiratory syndrome coronavirus 2","Rheumatoid arthritis"],"catalyst":""},{"name":"Prozac","genericName":"fluoxetine","slug":"fluoxetine","phase":"marketed","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown.","indications":["Bipolar affective disorder, current episode depression","Bulimia nervosa","Depressive disorder","Major depressive disorder","Obsessive-compulsive disorder"],"catalyst":""},{"name":"Cyramza","genericName":"RAMUCIRUMAB","slug":"ramucirumab","phase":"marketed","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread.","indications":["Adenocarcinoma of stomach","Liver cell carcinoma","Malignant neoplasm of colon and/or rectum","Malignant tumor of stomach","Non-small cell lung cancer"],"catalyst":""},{"name":"Omvoh","genericName":"MIRIKIZUMAB","slug":"mirikizumab","phase":"marketed","mechanism":"MIRIKIZUMAB blocks the activity of Interleukin-23, a protein involved in inflammation.","indications":["Ulcerative Colitis","Crohn's Disease"],"catalyst":""},{"name":"Retevmo","genericName":"SELPERCATINIB","slug":"selpercatinib","phase":"marketed","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells.","indications":["Advanced RET fusion-positive non-small cell lung cancer","Advanced RET fusion-positive thyroid cancer","Medullary thyroid carcinoma","Metastasis from malignant tumor of thyroid","Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Emgality","genericName":"GALCANEZUMAB","slug":"galcanezumab","phase":"marketed","mechanism":"Emgality works by binding to calcitonin gene-related peptide 1 (CGRP1), preventing it from triggering migraine attacks.","indications":["Preventive treatment of migraine","Treatment of episodic cluster headache"],"catalyst":""},{"name":"Zyprexa","genericName":"olanzapine","slug":"olanzapine","phase":"marketed","mechanism":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","indications":["Agitation associated with Bipolar Mania","Agitation associated with Schizophrenia","Bipolar affective disorder, current episode depression","Bipolar affective disorder, current episode manic","Bipolar disorder in remission"],"catalyst":""},{"name":"Cymbalta","genericName":"duloxetine","slug":"duloxetine","phase":"marketed","mechanism":"Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms.","indications":["Chronic Musculoskeletal Pain","Diabetic peripheral neuropathy","Female stress incontinence","Fibromyalgia","Generalized anxiety disorder"],"catalyst":""},{"name":"Humulin","genericName":"insulin","slug":"insulin","phase":"marketed","mechanism":"Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels.","indications":["Diabetes mellitus type 1","Diabetes mellitus type 2"],"catalyst":""},{"name":"Glargine","genericName":"Glargine","slug":"glargine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Inluriyo","genericName":"IMLUNESTRANT","slug":"imlunestrant","phase":"marketed","mechanism":"Inluriyo works by blocking estrogen receptors on cancer cells, preventing them from growing and spreading.","indications":["ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy"],"catalyst":""},{"name":"Strattera","genericName":"ATOMOXETINE","slug":"atomoxetine","phase":"marketed","mechanism":"Strattera works by blocking the reabsorption of norepinephrine in the brain, allowing more of this neurotransmitter to be available for use.","indications":["Attention deficit hyperactivity disorder"],"catalyst":""},{"name":"1121B","genericName":"1121B","slug":"1121b","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Alpha1 Blocker","genericName":"Alpha1 Blocker","slug":"alpha1-blocker","phase":"marketed","mechanism":"Alpha-1 blockers inhibit alpha-1 adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction.","indications":["Hypertension","Benign prostatic hyperplasia with lower urinary tract symptoms"],"catalyst":""},{"name":"Cialis","genericName":"tadalafil","slug":"tadalafil","phase":"marketed","mechanism":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","indications":["Benign prostatic hyperplasia","Impotence","Pulmonary hypertension"],"catalyst":""},{"name":"Cinobac","genericName":"CINOXACIN","slug":"cinoxacin","phase":"marketed","mechanism":"Carbonic anhydrase 2","indications":["Urinary tract infectious disease"],"catalyst":""},{"name":"Decabid","genericName":"INDECAINIDE","slug":"indecainide","phase":"marketed","mechanism":"Sodium channel protein type 5 subunit alpha","indications":[],"catalyst":""},{"name":"Dymelor","genericName":"ACETOHEXAMIDE","slug":"acetohexamide","phase":"marketed","mechanism":"Sulfonylurea receptor 1, Kir6.2","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Glargine Basal-Bolus Therapy","genericName":"Glargine Basal-Bolus Therapy","slug":"glargine-basal-bolus-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glucagon IM","genericName":"Glucagon IM","slug":"glucagon-im","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Glucagon Nasal Powder","genericName":"Glucagon Nasal Powder","slug":"glucagon-nasal-powder","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Human Insulin Inhalation Powder","genericName":"Human Insulin Inhalation Powder","slug":"human-insulin-inhalation-powder","phase":"phase_3","mechanism":"Human insulin delivered via inhalation powder replaces or supplements endogenous insulin to regulate blood glucose by promoting glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Huminsulin Regular","genericName":"Huminsulin Regular","slug":"huminsulin-regular","phase":"marketed","mechanism":"Huminsulin Regular is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro (U100)","genericName":"Insulin Lispro (U100)","slug":"insulin-lispro-u100","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Mix50","genericName":"Insulin Lispro Mix50","slug":"insulin-lispro-mix50","phase":"marketed","mechanism":"Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro-aabc","genericName":"Insulin Lispro-aabc","slug":"insulin-lispro-aabc","phase":"marketed","mechanism":"Insulin Lispro-aabc is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro 2 day reservoir in-use","genericName":"Insulin lispro 2 day reservoir in-use","slug":"insulin-lispro-2-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY2216684","genericName":"LY2216684","slug":"ly2216684","phase":"phase_3","mechanism":"LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.","indications":["Major depressive disorder","Circadian rhythm sleep disorders"],"catalyst":""},{"name":"LY2963016","genericName":"LY2963016","slug":"ly2963016","phase":"phase_3","mechanism":"LY2963016 is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY3537982","genericName":"LY3537982","slug":"ly3537982","phase":"phase_3","mechanism":"LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3650150","genericName":"LY3650150","slug":"ly3650150","phase":"phase_3","mechanism":"LY3650150 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3819469","genericName":"LY3819469","slug":"ly3819469","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3848575","genericName":"LY3848575","slug":"ly3848575","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3962673","genericName":"LY3962673","slug":"ly3962673","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4100511","genericName":"LY4100511","slug":"ly4100511","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4175408","genericName":"LY4175408","slug":"ly4175408","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY450139","genericName":"LY450139","slug":"ly450139","phase":"phase_3","mechanism":"LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein.","indications":["Alzheimer's disease (mild cognitive impairment and mild dementia stages)"],"catalyst":""},{"name":"LY451395","genericName":"LY451395","slug":"ly451395","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro Mixture Therapy","genericName":"Lispro Mixture Therapy","slug":"lispro-mixture-therapy","phase":"marketed","mechanism":"Lispro Mixture is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Metocurine","genericName":"dimethyltubocurarinium","slug":"dimethyltubocurarinium","phase":"marketed","mechanism":"Acetylcholine receptor","indications":["Muscle relaxation, function"],"catalyst":""},{"name":"Placebo (PLA)","genericName":"Placebo (PLA)","slug":"placebo-pla","phase":"marketed","mechanism":"Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous healing mechanisms independent of pharmacological action.","indications":["Control arm in randomized controlled trials across multiple therapeutic areas"],"catalyst":""},{"name":"aldrenodate","genericName":"aldrenodate","slug":"aldrenodate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"zuclopentixol","genericName":"zuclopentixol","slug":"zuclopentixol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ADP receptor inhibitors","genericName":"ADP receptor inhibitors","slug":"adp-receptor-inhibitors","phase":"phase_2","mechanism":"ADP receptor inhibitors block the action of ADP on its receptor, preventing platelet activation and aggregation.","indications":["Acute coronary syndrome","Myocardial infarction"],"catalyst":""},{"name":"ALIMTA plus Epirubicin","genericName":"ALIMTA plus Epirubicin","slug":"alimta-plus-epirubicin","phase":"phase_1","mechanism":"Topoisomerase I inhibitor","indications":["Non-small cell lung cancer","Mesothelioma"],"catalyst":""},{"name":"AM0010","genericName":"AM0010","slug":"am0010","phase":"phase_2","mechanism":"AM0010 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Alfarol 1.0 µg","genericName":"Alfarol 1.0 µg","slug":"alfarol-1-0-g","phase":"marketed","mechanism":"Alfarol is an active vitamin D analog that binds to the vitamin D receptor to regulate calcium and phosphate homeostasis.","indications":["Hypocalcemia and secondary hyperparathyroidism in chronic kidney disease","Hypoparathyroidism","Vitamin D-dependent rickets","Osteoporosis"],"catalyst":""},{"name":"Analog or Human Insulin","genericName":"Analog or Human Insulin","slug":"analog-or-human-insulin","phase":"phase_2","mechanism":"Human insulin analogs mimic the action of the body's natural insulin, helping to lower blood sugar levels.","indications":["Type 1 diabetes","Type 2 diabetes"],"catalyst":""},{"name":"Anastrozole, Exemestane, or Letrozole","genericName":"Anastrozole, Exemestane, or Letrozole","slug":"anastrozole-exemestane-or-letrozole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Any platinum-based doublet chemotherapy","genericName":"Any platinum-based doublet chemotherapy","slug":"any-platinum-based-doublet-chemotherapy","phase":"phase_2","mechanism":"Platinum-based doublet chemotherapy works by interfering with DNA replication in cancer cells, ultimately leading to cell death.","indications":["Non-small cell lung cancer","Small cell lung cancer","Ovarian cancer","Bladder cancer","Head and neck cancer"],"catalyst":""},{"name":"Axiron","genericName":"Axiron","slug":"axiron","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BEC2 Vaccine","genericName":"BEC2 Vaccine","slug":"bec2-vaccine","phase":"phase_3","mechanism":"BEC2 is a therapeutic cancer vaccine that targets the GD3 ganglioside antigen expressed on tumor cells to stimulate an immune response against cancer.","indications":["Small cell lung cancer (SCLC)","Melanoma"],"catalyst":""},{"name":"Background Chemotherapy","genericName":"Background Chemotherapy","slug":"background-chemotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Basal Insulin Analog","genericName":"Basal Insulin Analog","slug":"basal-insulin-analog","phase":"marketed","mechanism":"Basal insulin analogs mimic the body's natural background insulin secretion by binding to insulin receptors and promoting glucose uptake into cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Bevacizumab (Bev)","genericName":"Bevacizumab (Bev)","slug":"bevacizumab-bev","phase":"marketed","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Metastatic non-small cell lung cancer (in combination with chemotherapy)","Metastatic breast cancer (in combination with chemotherapy)","Glioblastoma (recurrent)","Metastatic renal cell carcinoma (in combination with interferon-alpha)"],"catalyst":""},{"name":"Biguanide (BG)","genericName":"Biguanide (BG)","slug":"biguanide-bg","phase":"phase_3","mechanism":"Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Biguanides (BG)","genericName":"Biguanides (BG)","slug":"biguanides-bg","phase":"phase_3","mechanism":"Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial glycerol-3-phosphate dehydrogenase.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Bortezomib IV","genericName":"Bortezomib IV","slug":"bortezomib-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brenipatide","genericName":"Brenipatide","slug":"brenipatide","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cephalotin","genericName":"cefalotin","slug":"cefalotin","phase":"marketed","mechanism":"Solute carrier family 22 member 8","indications":["Bacterial infection due to Klebsiella pneumoniae","Bacterial septicemia","Female genital tract infection","Genitourinary Tract Infections","Haemophilus influenzae pneumonia"],"catalyst":""},{"name":"Commercially-available Aspirin","genericName":"Commercially-available Aspirin","slug":"commercially-available-aspirin","phase":"phase_3","mechanism":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.","indications":["Acute myocardial infarction","Ischemic stroke prevention","Transient ischemic attack (TIA) prevention","Coronary artery disease","Mild to moderate pain"],"catalyst":""},{"name":"Dicurin Procaine","genericName":"MERETHOXYLLINE PROCAINE","slug":"merethoxylline-procaine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Digicor","genericName":"DIGITOXIN","slug":"digitoxin","phase":"marketed","mechanism":"Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1","indications":[],"catalyst":""},{"name":"Docetaxel (Taxane)","genericName":"Docetaxel (Taxane)","slug":"docetaxel-taxane","phase":"phase_3","mechanism":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Prostate cancer","Gastric cancer","Head and neck cancer"],"catalyst":""},{"name":"Dulaglutide Pen","genericName":"Dulaglutide Pen","slug":"dulaglutide-pen","phase":"marketed","mechanism":"Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus","Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease"],"catalyst":""},{"name":"Duloxetine (DLX)","genericName":"Duloxetine (DLX)","slug":"duloxetine-dlx","phase":"phase_3","mechanism":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","indications":["Major depressive disorder","Generalized anxiety disorder","Diabetic peripheral neuropathic pain","Fibromyalgia","Chronic musculoskeletal pain"],"catalyst":""},{"name":"Duloxetine Hydrochloride (HCI)","genericName":"Duloxetine Hydrochloride (HCI)","slug":"duloxetine-hydrochloride-hci","phase":"phase_3","mechanism":"Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","indications":["Major depressive disorder","Generalized anxiety disorder","Diabetic peripheral neuropathic pain","Fibromyalgia","Chronic musculoskeletal pain"],"catalyst":""},{"name":"Duloxetine hydrochloride - 60 mg","genericName":"Duloxetine hydrochloride - 60 mg","slug":"duloxetine-hydrochloride-60-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EBGLYSS","genericName":"LEBRIKIZUMAB-LBKZ","slug":"lebrikizumab-lbkz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"ERA as specific PAH treatment","genericName":"ERA as specific PAH treatment","slug":"era-as-specific-pah-treatment","phase":"phase_3","mechanism":"Endothelin receptor antagonists (ERAs) block endothelin-1 signaling in pulmonary vasculature to reduce vasoconstriction and improve hemodynamics in pulmonary arterial hypertension.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"Ebglyss","genericName":"LEBRIKIZUMAB","slug":"lebrikizumab","phase":"marketed","mechanism":"Ebglyss works by binding to interleukin-13, a protein that promotes inflammation in the skin.","indications":["Moderate-to-severe atopic dermatitis"],"catalyst":""},{"name":"Eramin","genericName":"HISTAMINE","slug":"histamine","phase":"marketed","mechanism":"Histamine H3 receptor","indications":["Acute myeloid leukemia, disease","Hyposensitization to allergens","Osteoarthritis"],"catalyst":""},{"name":"Erbitux (Cetuximab)","genericName":"Erbitux (Cetuximab)","slug":"erbitux-cetuximab","phase":"phase_3","mechanism":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing tumor growth and survival signals.","indications":["Metastatic colorectal cancer (KRAS wild-type)","Squamous cell carcinoma of the head and neck","Non-small cell lung cancer"],"catalyst":""},{"name":"Evista","genericName":"RALOXIFENE","slug":"raloxifene","phase":"marketed","mechanism":"Raloxifene binds to estrogen receptors, acting as an agonist in bone and an antagonist in uterine and breast tissues.","indications":["Postmenopausal osteoporosis","Prevention of Breast Carcinoma"],"catalyst":""},{"name":"Exenatide once weekly (QW)","genericName":"Exenatide once weekly (QW)","slug":"exenatide-once-weekly-qw","phase":"marketed","mechanism":"Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Exenatide twice daily (BID)","genericName":"Exenatide twice daily (BID)","slug":"exenatide-twice-daily-bid","phase":"marketed","mechanism":"Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Glinides","genericName":"Glinides","slug":"glinides","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glucagon Hydrochloride Solution","genericName":"Glucagon Hydrochloride Solution","slug":"glucagon-hydrochloride-solution","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes mellitus","Diagnostic aid in radiologic examination of the gastrointestinal tract"],"catalyst":""},{"name":"Humalog Mix 50","genericName":"Humalog Mix 50","slug":"humalog-mix-50","phase":"phase_3","mechanism":"Humalog Mix 50 is a combination insulin therapy that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Human Insulin Mix 50:50","genericName":"Human Insulin Mix 50:50","slug":"human-insulin-mix-50-50","phase":"phase_3","mechanism":"Human Insulin Mix 50:50 replaces deficient endogenous insulin by binding to insulin receptors on target cells to promote glucose uptake and utilization.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Human Regular U-500 Insulin","genericName":"Human Regular U-500 Insulin","slug":"human-regular-u-500-insulin","phase":"marketed","mechanism":"Human Regular U-500 Insulin is a concentrated insulin formulation that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (particularly in insulin-resistant patients requiring high doses)"],"catalyst":""},{"name":"Human insulin 30/70","genericName":"Human insulin 30/70","slug":"human-insulin-30-70","phase":"marketed","mechanism":"Human insulin 30/70 is a fixed-ratio combination of 30% short-acting insulin and 70% intermediate-acting insulin that replaces endogenous insulin to regulate blood glucose by promoting cellular glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Human insulin isophane suspension","genericName":"Human insulin isophane suspension","slug":"human-insulin-isophane-suspension","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IMC-1121B","genericName":"IMC-1121B","slug":"imc-1121b","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IMC-18F1","genericName":"IMC-18F1","slug":"imc-18f1","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Injectable insulin","genericName":"Injectable insulin","slug":"injectable-insulin","phase":"marketed","mechanism":"Injectable insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating cellular glucose uptake and storage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (when oral agents are insufficient)"],"catalyst":""},{"name":"Insulin Analog Mid Mixture","genericName":"Insulin Analog Mid Mixture","slug":"insulin-analog-mid-mixture","phase":"marketed","mechanism":"This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Aspart 6 Day (6D)","genericName":"Insulin Aspart 6 Day (6D)","slug":"insulin-aspart-6-day-6d","phase":"phase_3","mechanism":"Insulin Aspart 6 Day is a long-acting basal insulin analog designed to provide extended glucose control with a 6-day duration of action.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Biphasic Aspart 30/70","genericName":"Insulin Biphasic Aspart 30/70","slug":"insulin-biphasic-aspart-30-70","phase":"marketed","mechanism":"Insulin biphasic aspart 30/70 is a premixed insulin combining 30% rapid-acting aspart and 70% intermediate-acting aspart to provide both immediate and sustained blood glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro 6 Day (6D)","genericName":"Insulin Lispro 6 Day (6D)","slug":"insulin-lispro-6-day-6d","phase":"phase_3","mechanism":"Insulin Lispro 6 Day is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Mix25","genericName":"Insulin Lispro Mix25","slug":"insulin-lispro-mix25","phase":"marketed","mechanism":"Insulin Lispro Mix25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Premix","genericName":"Insulin Lispro Premix","slug":"insulin-lispro-premix","phase":"marketed","mechanism":"Insulin lispro premix is a fixed combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics physiologic insulin secretion by providing both mealtime and basal glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro Protamine Suspension","genericName":"Insulin Lispro Protamine Suspension","slug":"insulin-lispro-protamine-suspension","phase":"marketed","mechanism":"Insulin lispro protamine suspension is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and storage, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin Lispro low mixture","genericName":"Insulin Lispro low mixture","slug":"insulin-lispro-low-mixture","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin aspart 6 day reservoir in-use","genericName":"Insulin aspart 6 day reservoir in-use","slug":"insulin-aspart-6-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro (Humalog)","genericName":"Insulin lispro (Humalog)","slug":"insulin-lispro-humalog","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro 6 day reservoir in-use","genericName":"Insulin lispro 6 day reservoir in-use","slug":"insulin-lispro-6-day-reservoir-in-use","phase":"phase_3","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro A","genericName":"Insulin lispro A","slug":"insulin-lispro-a","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro B","genericName":"Insulin lispro B","slug":"insulin-lispro-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Insulin lispro low mix","genericName":"Insulin lispro low mix","slug":"insulin-lispro-low-mix","phase":"marketed","mechanism":"Insulin lispro low mix is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiological insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin lispro mix 25","genericName":"Insulin lispro mix 25","slug":"insulin-lispro-mix-25","phase":"phase_3","mechanism":"Insulin lispro mix 25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Intramuscular Glucagon","genericName":"Intramuscular Glucagon","slug":"intramuscular-glucagon","phase":"phase_3","mechanism":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Intramuscular Olanzapine Depot","genericName":"Intramuscular Olanzapine Depot","slug":"intramuscular-olanzapine-depot","phase":"phase_3","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia maintenance treatment","Bipolar I disorder maintenance treatment"],"catalyst":""},{"name":"Ixekizumab Auto-Injector","genericName":"Ixekizumab Auto-Injector","slug":"ixekizumab-auto-injector","phase":"phase_3","mechanism":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"Ixekizumab Prefilled Syringe","genericName":"Ixekizumab Prefilled Syringe","slug":"ixekizumab-prefilled-syringe","phase":"marketed","mechanism":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"KISUNLA","genericName":"DONANEMAB-AZBT","slug":"donanemab-azbt","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Kafocin","genericName":"cefaloglycin","slug":"cefaloglycin","phase":"marketed","mechanism":"Bacterial penicillin-binding protein","indications":[],"catalyst":""},{"name":"Kappadione","genericName":"MENADIOL SODIUM DIPHOSPHATE","slug":"menadiol-sodium-diphosphate","phase":"marketed","mechanism":"Small molecule","indications":["Hemorrhage","Obstructive hyperbilirubinemia"],"catalyst":""},{"name":"Kefadol","genericName":"CEFAMANDOLE NAFATE","slug":"cefamandole-nafate","phase":"marketed","mechanism":"Kefadol works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","indications":[],"catalyst":""},{"name":"LOXO-305","genericName":"LOXO-305","slug":"loxo-305","phase":"phase_2","mechanism":"Selective Bruton's tyrosine kinase (BTK) inhibitor","indications":["Relapsed or refractory mantle cell lymphoma","Relapsed or refractory marginal zone lymphoma"],"catalyst":""},{"name":"LOXO-783","genericName":"LOXO-783","slug":"loxo-783","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2062430","genericName":"LY2062430","slug":"ly2062430","phase":"phase_3","mechanism":"LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain.","indications":["Huntington's disease"],"catalyst":""},{"name":"LY2189265","genericName":"LY2189265","slug":"ly2189265","phase":"phase_3","mechanism":"LY2189265 is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1 to improve blood glucose control by stimulating insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY2189265 and Lifestyle Measures","genericName":"LY2189265 and Lifestyle Measures","slug":"ly2189265-and-lifestyle-measures","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2196044","genericName":"LY2196044","slug":"ly2196044","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2216684 (edivoxetine)","genericName":"LY2216684 (edivoxetine)","slug":"ly2216684-edivoxetine","phase":"phase_3","mechanism":"LY2216684 (edivoxetine) is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.","indications":["Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"LY2422347","genericName":"LY2422347","slug":"ly2422347","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2541546 - SC","genericName":"LY2541546 - SC","slug":"ly2541546-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2584702 Reference Formulation","genericName":"LY2584702 Reference Formulation","slug":"ly2584702-reference-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2603618","genericName":"LY2603618","slug":"ly2603618","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY2605541","genericName":"LY2605541","slug":"ly2605541","phase":"phase_3","mechanism":"LY2605541 is a long-acting basal insulin analog that binds to the insulin receptor to lower blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY2787106","genericName":"LY2787106","slug":"ly2787106","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3016859","genericName":"LY3016859","slug":"ly3016859","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3457263","genericName":"LY3457263","slug":"ly3457263","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3502970","genericName":"LY3502970","slug":"ly3502970","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY353381","genericName":"LY353381","slug":"ly353381","phase":"phase_3","mechanism":"LY353381 is a selective estrogen receptor modulator (SERM) that acts as a partial agonist at estrogen receptors to provide bone-protective and cardiovascular benefits without stimulating breast or endometrial tissue.","indications":["Osteoporosis prevention and treatment in postmenopausal women","Cardiovascular risk reduction in postmenopausal women"],"catalyst":""},{"name":"LY3537031","genericName":"LY3537031","slug":"ly3537031","phase":"phase_3","mechanism":"LY3537031 is a GLP-1 and GIP receptor dual agonist that activates both incretin pathways to improve glucose control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3819253","genericName":"LY3819253","slug":"ly3819253","phase":"phase_3","mechanism":"LY3819253 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY3832479","genericName":"LY3832479","slug":"ly3832479","phase":"phase_2","mechanism":"LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9).","indications":["Metastatic non-small cell lung cancer","Metastatic triple-negative breast cancer"],"catalyst":""},{"name":"LY3838915","genericName":"LY3838915","slug":"ly3838915","phase":"phase_2","mechanism":"LY3838915 is a small molecule that targets the CDK9 protein.","indications":["Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"LY3839840","genericName":"LY3839840","slug":"ly3839840","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY3857210","genericName":"LY3857210","slug":"ly3857210","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4057996 IV","genericName":"LY4057996 IV","slug":"ly4057996-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY4065967","genericName":"LY4065967","slug":"ly4065967","phase":"phase_2","mechanism":"LY4065967 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.","indications":["FGFR-altered solid tumors (Phase 2 development)"],"catalyst":""},{"name":"LY573636-sodium","genericName":"LY573636-sodium","slug":"ly573636-sodium","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY900003","genericName":"LY900003","slug":"ly900003","phase":"phase_3","mechanism":"LY900003 is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"LY900014","genericName":"LY900014","slug":"ly900014","phase":"phase_3","mechanism":"LY900014 is a rapid-acting insulin lispro formulation that mimics endogenous insulin by binding to insulin receptors to facilitate glucose uptake and metabolism.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lartruvo","genericName":"OLARATUMAB","slug":"olaratumab","phase":"marketed","mechanism":"Platelet-derived growth factor receptor alpha","indications":["Sarcoma of soft tissue"],"catalyst":""},{"name":"Lebrikizumab Pen","genericName":"Lebrikizumab Pen","slug":"lebrikizumab-pen","phase":"phase_3","mechanism":"Lebrikizumab is a monoclonal antibody that blocks interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammation.","indications":["Moderate-to-severe atopic dermatitis","Uncontrolled asthma with type 2 inflammation"],"catalyst":""},{"name":"Lispro","genericName":"Lispro","slug":"lispro","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro Low Mix","genericName":"Lispro Low Mix","slug":"lispro-low-mix","phase":"marketed","mechanism":"Lispro Low Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Mid Mix","genericName":"Lispro Mid Mix","slug":"lispro-mid-mix","phase":"marketed","mechanism":"Lispro Mid Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics the body's natural insulin secretion pattern by providing both immediate and sustained glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Mix 50/50","genericName":"Lispro Mix 50/50","slug":"lispro-mix-50-50","phase":"marketed","mechanism":"Lispro Mix 50/50 is a combination insulin that provides both rapid-acting and intermediate-acting insulin to control blood glucose in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Lispro Prandial Insulin","genericName":"Lispro Prandial Insulin","slug":"lispro-prandial-insulin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lispro mix 75/25","genericName":"Lispro mix 75/25","slug":"lispro-mix-75-25","phase":"marketed","mechanism":"Lispro mix 75/25 is a combination insulin that provides rapid-acting insulin coverage for mealtime glucose spikes plus intermediate-acting basal insulin for baseline glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Ly-Cov016","genericName":"ETESEVIMAB","slug":"etesevimab","phase":"marketed","mechanism":"Monoclonal antibody","indications":["COVID-19"],"catalyst":""},{"name":"Ly-Cov555","genericName":"BAMLANIVIMAB","slug":"bamlanivimab","phase":"discontinued","mechanism":"Ly-Cov555 works by binding to the SARS-CoV-2 virus and preventing it from entering host cells.","indications":["COVID-19"],"catalyst":""},{"name":"Menadion","genericName":"MENADIONE","slug":"menadione","phase":"marketed","mechanism":"Aldehyde oxidase, Alpha-synuclein, Dual specificity phosphatase Cdc25A","indications":[],"catalyst":""},{"name":"Metholone","genericName":"drostanolone propionate","slug":"drostanolone-propionate","phase":"marketed","mechanism":"Androgen receptor","indications":["Malignant neoplasm of breast"],"catalyst":""},{"name":"Moxam","genericName":"latamoxef","slug":"latamoxef","phase":"marketed","mechanism":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","indications":[],"catalyst":""},{"name":"Nasal Glucagon (NG)","genericName":"Nasal Glucagon (NG)","slug":"nasal-glucagon-ng","phase":"phase_3","mechanism":"Nasal glucagon activates glucagon receptors to rapidly increase blood glucose levels in hypoglycemic emergencies.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Neutral protamine hagedorn insulin","genericName":"Neutral protamine hagedorn insulin","slug":"neutral-protamine-hagedorn-insulin","phase":"marketed","mechanism":"NPH insulin is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"OAMs","genericName":"OAMs","slug":"oams","phase":"phase_3","mechanism":"OAMs are oral antidiabetic agents that work through multiple mechanisms to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"OMVOH","genericName":"MIRIKIZUMAB-MRKZ","slug":"mirikizumab-mrkz","phase":"marketed","mechanism":"Interleukin-23 subunit alpha","indications":["Moderately to severely active ulcerative colitis"],"catalyst":""},{"name":"Oral Olanzapine","genericName":"Oral Olanzapine","slug":"oral-olanzapine","phase":"marketed","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Agitation associated with schizophrenia or bipolar disorder","Adjunctive treatment of major depressive disorder"],"catalyst":""},{"name":"Oral antihyperglycemics","genericName":"Oral antihyperglycemics","slug":"oral-antihyperglycemics","phase":"phase_3","mechanism":"Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Osmotic-release oral system methylphenidate","genericName":"Osmotic-release oral system methylphenidate","slug":"osmotic-release-oral-system-methylphenidate","phase":"marketed","mechanism":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adults","Narcolepsy"],"catalyst":""},{"name":"Other standard therapy for ADHD","genericName":"Other standard therapy for ADHD","slug":"other-standard-therapy-for-adhd","phase":"phase_3","mechanism":"This represents a standard ADHD therapy from Eli Lilly, likely a stimulant or non-stimulant that increases dopamine and/or norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.","indications":["Attention-Deficit/Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"PPAR alpha","genericName":"PPAR alpha","slug":"ppar-alpha","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Paclitaxel (Taxane)","genericName":"Paclitaxel (Taxane)","slug":"paclitaxel-taxane","phase":"phase_3","mechanism":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic carcinoma of the ovary","Breast cancer (metastatic and adjuvant)","Non-small cell lung cancer","Kaposi's sarcoma","Gastric adenocarcinoma"],"catalyst":""},{"name":"Pagitane","genericName":"CYCRIMINE","slug":"cycrimine","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M1","indications":["Parkinson's disease"],"catalyst":""},{"name":"Pemetrexed Phase 2","genericName":"Pemetrexed Phase 2","slug":"pemetrexed-phase-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo (for Ramucirumab)","genericName":"Placebo (for Ramucirumab)","slug":"placebo-for-ramucirumab","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo as Capsules","genericName":"Placebo as Capsules","slug":"placebo-as-capsules","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.","indications":["Control arm in phase 3 clinical trials (specific indication unknown)"],"catalyst":""},{"name":"Placebo every 2 weeks","genericName":"Placebo every 2 weeks","slug":"placebo-every-2-weeks","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo every 4 weeks","genericName":"Placebo every 4 weeks","slug":"placebo-every-4-weeks","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo for Abemaciclib","genericName":"Placebo for Abemaciclib","slug":"placebo-for-abemaciclib","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in phase 3 clinical trials of abemaciclib"],"catalyst":""},{"name":"Placebo-Oral","genericName":"Placebo-Oral","slug":"placebo-oral","phase":"marketed","mechanism":"Placebo produces no pharmacological effect and works entirely through the placebo effect, a psychobiological response to the expectation of treatment.","indications":["Clinical trial control comparator (not a therapeutic indication)"],"catalyst":""},{"name":"Platinol","genericName":"Platinol","slug":"platinol","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Portrazza","genericName":"NECITUMUMAB","slug":"necitumumab","phase":"marketed","mechanism":"Portrazza works by blocking the epidermal growth factor receptor (EGFR) protein, which is involved in cancer cell growth and proliferation.","indications":["Non-small cell lung cancer","Squamous non-small cell lung cancer"],"catalyst":""},{"name":"Prandial Insulin Lispro","genericName":"Prandial Insulin Lispro","slug":"prandial-insulin-lispro","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood sugar levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Quinidine Gluconate","genericName":"QUINIDINE SULFATE","slug":"quinidine-sulfate","phase":"marketed","mechanism":"Quinidine Gluconate works by blocking the M2 muscarinic acetylcholine receptor, which helps regulate heart rhythm.","indications":["Atrial fibrillation","Cardioversion of Atrial Fibrillation","Life-Threatening Ventricular Tachycardia","Malaria","Pseudobulbar affect"],"catalyst":""},{"name":"Raloxifene HCL","genericName":"Raloxifene HCL","slug":"raloxifene-hcl","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ramucirumab (IMC-1211B) DP","genericName":"Ramucirumab (IMC-1211B) DP","slug":"ramucirumab-imc-1211b-dp","phase":"phase_3","mechanism":"Ramucirumab is a monoclonal antibody that blocks vascular endothelial growth factor receptor 2 (VEGFR2) to inhibit tumor angiogenesis and vascular growth.","indications":["Metastatic non-small cell lung cancer (in combination with docetaxel)","Gastric or gastroesophageal junction adenocarcinoma (in combination with chemotherapy)","Metastatic colorectal cancer (in combination with FOLFIRI)","Hepatocellular carcinoma (in combination with atezolizumab)"],"catalyst":""},{"name":"Ramucirumab - SC","genericName":"Ramucirumab - SC","slug":"ramucirumab-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ramucirumab DP","genericName":"Ramucirumab DP","slug":"ramucirumab-dp","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ramucirumab DP (IMC-1121B)","genericName":"Ramucirumab DP (IMC-1121B)","slug":"ramucirumab-dp-imc-1121b","phase":"phase_3","mechanism":"Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","indications":["Non-small cell lung cancer, gastric cancer, and other solid tumors"],"catalyst":""},{"name":"Rapid Acting Intramuscular Olanzapine","genericName":"Rapid Acting Intramuscular Olanzapine","slug":"rapid-acting-intramuscular-olanzapine","phase":"phase_3","mechanism":"Olanzapine is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.","indications":["Treatment of schizophrenia","Treatment of bipolar disorder"],"catalyst":""},{"name":"Remternetug (IV)","genericName":"Remternetug (IV)","slug":"remternetug-iv","phase":"phase_3","mechanism":"Remternetug is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Remternetug (SC)","genericName":"Remternetug (SC)","slug":"remternetug-sc","phase":"phase_3","mechanism":"Remternetug is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Reyvow","genericName":"LASMIDITAN","slug":"lasmiditan","phase":"marketed","mechanism":"Reyvow works by binding to the 5-HT1F receptor, blocking pain signals in the brain.","indications":["Migraine"],"catalyst":""},{"name":"Salmon Calcitonin","genericName":"Salmon Calcitonin","slug":"salmon-calcitonin","phase":"marketed","mechanism":"Salmon calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and lower serum calcium levels.","indications":["Paget's disease of bone","Hypercalcemia of malignancy","Osteoporosis in postmenopausal women","Acute bone loss following immobilization"],"catalyst":""},{"name":"Sofetabart Mipitecan","genericName":"Sofetabart Mipitecan","slug":"sofetabart-mipitecan","phase":"phase_3","mechanism":"Sofetabart Mipitecan is a folic acid antagonist that inhibits thymidylate synthase.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"Somatropin (rDNA origin)","genericName":"Somatropin (rDNA origin)","slug":"somatropin-rdna-origin","phase":"phase_3","mechanism":"Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.","indications":["Growth hormone deficiency in children","Growth hormone deficiency in adults","Short stature associated with Turner syndrome","Chronic kidney disease-related growth failure"],"catalyst":""},{"name":"Standard therapy for INCS","genericName":"Standard therapy for INCS","slug":"standard-therapy-for-incs","phase":"phase_3","mechanism":"Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.","indications":["Type 2 diabetes","Polycystic ovary syndrome (PCOS)"],"catalyst":""},{"name":"Stimulants","genericName":"Stimulants","slug":"stimulants","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sulfadiazine","genericName":"SULFADIAZINE","slug":"sulfadiazine","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 2A","indications":["Burn Wound Infections","Chorioretinitis","Congenital toxoplasmosis","Encephalitis due to Toxoplasmosis","Minor Bacterial Skin Infections"],"catalyst":""},{"name":"Tadalafil 5 mg","genericName":"Tadalafil 5 mg","slug":"tadalafil-5-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topical Corticosteroid (TCS)","genericName":"Topical Corticosteroid (TCS)","slug":"topical-corticosteroid-tcs","phase":"phase_3","mechanism":"Topical corticosteroids reduce inflammation by suppressing the immune system's response to perceived threats.","indications":["Eczema","Psoriasis","Dermatitis"],"catalyst":""},{"name":"Triamcinolone (Optional)","genericName":"Triamcinolone (Optional)","slug":"triamcinolone-optional","phase":"marketed","mechanism":"Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","indications":["Inflammatory and allergic conditions (dermatitis, eczema, psoriasis)","Rheumatoid arthritis and other joint disorders","Respiratory conditions (asthma, COPD)","Adrenocortical insufficiency","Systemic lupus erythematosus and other autoimmune diseases"],"catalyst":""},{"name":"Ultra-Rapid Lispro","genericName":"Ultra-Rapid Lispro","slug":"ultra-rapid-lispro","phase":"phase_3","mechanism":"Ultra-Rapid Lispro is a rapid-acting insulin analog that works by stimulating insulin release from the pancreas.","indications":["Treatment of diabetes mellitus"],"catalyst":""},{"name":"Vepugratinib","genericName":"Vepugratinib","slug":"vepugratinib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[^13C4D3^15N]-baricitinib","genericName":"[^13C4D3^15N]-baricitinib","slug":"13c4d3-15n-baricitinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"antiresorptives","genericName":"antiresorptives","slug":"antiresorptives","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"cDMARD","genericName":"cDMARD","slug":"cdmard","phase":"phase_3","mechanism":"cDMARDs work by inhibiting the enzyme peptidyl arginine deiminase, which is involved in the production of autoantibodies.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Juvenile idiopathic arthritis"],"catalyst":""},{"name":"injected insulin","genericName":"injected insulin","slug":"injected-insulin","phase":"phase_3","mechanism":"Injected insulin works by mimicking the action of the body's natural insulin hormone, helping to lower blood sugar levels.","indications":["Type 1 diabetes","Type 2 diabetes"],"catalyst":""},{"name":"insulin lispro LM","genericName":"insulin lispro LM","slug":"insulin-lispro-lm","phase":"marketed","mechanism":"Insulin lispro LM is a premixed insulin formulation that combines rapid-acting insulin lispro with intermediate-acting insulin to provide both mealtime and basal glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"insulin lispro MM","genericName":"insulin lispro MM","slug":"insulin-lispro-mm","phase":"marketed","mechanism":"Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"olanzapine pamoate depot","genericName":"olanzapine pamoate depot","slug":"olanzapine-pamoate-depot","phase":"phase_3","mechanism":"Olanzapine pamoate depot is a long-acting intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia (maintenance treatment)","Bipolar I disorder (maintenance treatment)"],"catalyst":""},{"name":"olanzapine therapy","genericName":"olanzapine therapy","slug":"olanzapine-therapy","phase":"marketed","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Acute agitation associated with schizophrenia or bipolar disorder","Treatment-resistant depression (in combination with fluoxetine)"],"catalyst":""},{"name":"placebo (tadalafil)","genericName":"placebo (tadalafil)","slug":"placebo-tadalafil","phase":"phase_3","mechanism":"Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor, which works by increasing blood flow to the penis to treat erectile dysfunction.","indications":["Erectile dysfunction"],"catalyst":""},{"name":"premeal insulin lispro mixtures","genericName":"premeal insulin lispro mixtures","slug":"premeal-insulin-lispro-mixtures","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"raloxifene HCI and alendronate Na","genericName":"raloxifene HCI and alendronate Na","slug":"raloxifene-hci-and-alendronate-na","phase":"marketed","mechanism":"This combination drug uses a selective estrogen receptor modulator (raloxifene) to reduce bone resorption and a bisphosphonate (alendronate) to inhibit osteoclast-mediated bone loss, together strengthening bone density.","indications":["Postmenopausal osteoporosis prevention and treatment"],"catalyst":""},{"name":"ramucirumab (IMC-1121B)","genericName":"ramucirumab (IMC-1121B)","slug":"ramucirumab-imc-1121b","phase":"phase_3","mechanism":"Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","indications":["Metastatic gastric cancer","Non-small cell lung cancer","Advanced or metastatic breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPVERlam85djVqVVRYa0JnZzZ5VmN3Vm9TZ1RzZWFwN2toeklwWlhEalgyWC1icjlPQ3ppaWE1eFA0UER5cktILXRfYWpIVWJMMlJ1X2tUcjkxLXVIMnVsYkZnRGdtSUZUVVd4Um9KTXdHLUdxd2REWHdpWE5SUDVkQzVjUFlkOG5RMU1lM0JySjJQMXZ4MXJFQmZlVTJ6M1RIZlZIRkFDRjNHd21ob3VUVnNSU2RnZ3Nxek5EX2ZWTQ?oc=5","date":"2026-04-08","type":"pipeline","source":"BioSpace","summary":"Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma - BioSpace","headline":"Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9YSjFiZWF5QzV2THBJMWl6ZnFYNUhTQy1Bd0lOTl90NlE0QjZUMW9oXzVGbHU5QlVvczRKNkNhZTVUVGVGdk9ybkhXbi1nUG5EeUM5d2Vwblp5MXdrZzNFdm93RnUzTWhHQ0E1NVNnbw?oc=5","date":"2026-04-08","type":"deal","source":"medwatch.com","summary":"Eli Lilly pays USD 12.5m to expand Alzheimer's collaboration - medwatch.com","headline":"Eli Lilly pays USD 12.5m to expand Alzheimer's collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBac1FwZDV1bWdyNnVYWW95TjZnTXJlRV9rREFwVEx1MEk3N18tLW1acXdWc3dnOGNLd3V0SGU3WTc4aFdfZF9vNVoyOXd4dGZQSmdXWFR3T1RPMVdLd09sVmVFd0pVLUdvT2d5NWZuaVRBdFpvVlE?oc=5","date":"2026-04-07","type":"trial","source":"Endpoints News","summary":"Eli Lilly's latest acquisition could preview another booming market - Endpoints News","headline":"Eli Lilly's latest acquisition could preview another booming market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxObkwyUGVqQWxCeHdveTU1MVNmOXpPdFQyN0F3SDkzWVdiUmsxSGJnbF8tV19BOWhHcUhGWV81a2U4SnpZYngtMm1oRUl3aUZGNWdiMUpDRk1idHhrak1BYlYtQnRPc1djQmVocnUwc3lKNWVVRFAwSzRFZU94eDdqR1Z0aDRWeXFDS2ZHSlNOVVdhYnN3dUFfb1htdEJldk1faFJxakxB?oc=5","date":"2026-04-07","type":"deal","source":"The Pharma Letter","summary":"AC Immune amends license and collaboration deal with Lilly - The Pharma Letter","headline":"AC Immune amends license and collaboration deal with Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQSkVPVnhIa19PekhBR1dXRUU4LUFkWG1heVVrOVctalc2SmJEVWp0azU2Tk5kOXc5R3hRdE9oYlc1SXpTYjRIWWVuZkhFTklPRnVMcDdmNkJmUzF2RC1QQ2xMY3ZFV0JvblJvWWFwekFBeFpOQlJtOUxYNHduQWpNcnFwR1hTbzgtZW1KV2hzUWF6bWZJSzl6VWRtRGFEZ2NVX1QtVjNYdDNNLVkzVHk0?oc=5","date":"2026-04-06","type":"pipeline","source":"Fierce Pharma","summary":"Eli Lilly takes the court with 150th anniversary campaign to catch Final Four crowd - Fierce Pharma","headline":"Eli Lilly takes the court with 150th anniversary campaign to catch Final Four crowd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOZ1ByUmp4YWRCRFJ5MDZPTURza3hCbFpBWm9GTHJTVGstTFQySHAtRUFMWWlvckh5dG5KRVZFNWZkWDEwN3lYSWk1VmVjeHBQOFZKYUEwaElGQk54UEs3REw1UUJfUUN3TFdRdzhtNmVYOXNEVFhTeHNTVTExSnZhblBIbmtKM0RGbllpcmhNcUEtWUswdlh5enQ2bWh3T25MUEM0Yi1na1JvSUhZ?oc=5","date":"2026-03-31","type":"deal","source":"WSJ","summary":"Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion - WSJ","headline":"Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPUEFweWxEQzVTeFJ2T2cxS3VDREdTMldDTlEwMW1DMGFMdHV2c0NveE9NRHdkd3phVmduVUxlNzBhOGxsTTFCRkptLV9YSDFOUm5wbk5DYXMwSVZXYXJGbW9zc29uM0h1MFFaZnRvRzlmdmZsTktoeG5WTHV2bEYySnFmMzF6c3V5T0ZCanp3eVVZVU5KMklySURDLVNEWmd2YWNF?oc=5","date":"2026-03-31","type":"deal","source":"Reuters","summary":"Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet - Reuters","headline":"Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE8wZTB2S29Tdlc4ZUxkX0VBb2JTZEZhbWJ6V1ZXRWp5eGZnTkFQSkQwSnA2WUxUdlhfaFV5WDlxajdIT3dJMjBOYW1ia0VoYk5oNFNrOWgweTB5cGZGbGxhVTMwWTVJM3RGZ2piUUU3akhxcWk5REJhSVRQblVkOWM?oc=5","date":"2026-03-31","type":"deal","source":"statnews.com","summary":"Eli Lilly to buy Centessa Pharmaceuticals, maker of a narcolepsy drug, in $6.3B deal - statnews.com","headline":"Eli Lilly to buy Centessa Pharmaceuticals, maker of a narcolepsy drug, in $6.3B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNUTA2aXNXNUNnTWJtcGw1R3V5VWYwZFdaSGpjZ0NIMzlsSTJtN2l5aG1PbGMyd1RzVVZIRThNUUl1Q1R2dGRzNXR0ZV90czBsYmNxS0M2UVR4NW94clRSdWxCMVJocGsyNHVqejZSdUxqSVU0b0NVR2RRUUtLdkhialZpUzJpdnYyVlZyWVdrWGpwSjlJbVHSAZsBQVVfeXFMT2pxaXFvZ0ZteUNrOFdyRl9PaGgtemg5QmYtWE9wNExGLUlmX3JqaVpaNVQ3bFNCcUh0NFNkXzJNMV9Ya2FZQTFKd1EwZGZ4YjZiaG55YU9BakdZajJqc3Axa29zZzRjd29VTEdFczI3TVB4UmljZjk3cmh4YXFHOVVXYV9sMFZkaHR5eU5aVUpPZkZCTXhSbDdES1k?oc=5","date":"2026-03-31","type":"deal","source":"CNBC","summary":"Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs - CNBC","headline":"Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOVWhMUDZXUGw0c0l3eWZtVUdZT1kxTUdBMURzWlRKV1VRRkFEc3Rucm1oNlpkUE1wSFlDTWl6OHRtcXhUR2t1b184enRCbHFsTEZDdkZSOXhsU3BfREdodlJWbXdNVUsxeDk5bXN0UUhCOWJRMzBVRVZPZ2pWR3FYWmVJa2tFdk1BajlrOVlRaGFoODZTX0ZJN245THNaakJyNU1hN1BqUdIBrAFBVV95cUxOOE9JZ1d4bktHYnBwa3VWVXZ4enI4YWVjcmdrUTVKZWl3bGlXaTdKcTlDZ2NBTkNpTHBmQ212TkhrZDUybFNYSWZsVENmWC1QTjZHQ1JpeElkdWpCVUZHRTAyNTMyRllTdWNWYlBMUGMyRW5xSlVac3ZmNG12bHNxSlFFdGlOdmhLMk1ncV9aWkw0RFFYQkh5eDVFcGJSOGdmNUxKdlpZVW5mb01a?oc=5","date":"2026-03-29","type":"deal","source":"CNBC","summary":"Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market - CNBC","headline":"Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOSFhDZG9vY01ONzRSOFhKeDkxUGFPN254WmZQcHhIYnExUm9wR3lHSzNuOU9VRmdyZncwX2ZTS1M3ZE1XRzRMVEVFTEpLV3dGX1FmZHJvR1J4WmNOR2loRjFvVmhrdWNKeXIzQnpNZzkwSDFoQVFCUTVMVkFaMy1NcXVXZmFDVFZ0UUF3bXU3MjdHZ0VlaHVUQWhxd19jelVEOTF5UkktaHdRbDh3QmlHU1FaSzcwQ05XcWZ2QTlR?oc=5","date":"2026-03-12","type":"pipeline","source":"Fierce Pharma","summary":"In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12 - Fierce Pharma","headline":"In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOUkx2LUh4MTJFay1RMjRlZVdhMHpoWmo0aWx2YUxTUmhPb1ZCMkRsREJQRHNfYjhLUU9XMGZ1UFU4ZzVNeHNtbldGVUJNWGxjOGtTMnZvTDgybmFrakRQZkFOZGFibnN0N2JER0lvTmpaQmFQWS1oMGROOGFvdlJ3aWJ5bFFVTWM3VktranpLX0NqUmdCXzBhSjhUS1ZrM2dvaGM0?oc=5","date":"2026-03-05","type":"pipeline","source":"fiercehealthcare.com","summary":"Eli Lilly launches its direct-to-employer platform for GLP-1s - fiercehealthcare.com","headline":"Eli Lilly launches its direct-to-employer platform for GLP-1s","sentiment":"neutral"}],"patents":[{"drugName":"Retevmo","drugSlug":"selpercatinib","patentNumber":"10584124","type":"Compound","expiryDate":"2038-10-10","territory":"US","annualRevenue":700000000,"genericFilings":[]},{"drugName":"Retevmo","drugSlug":"selpercatinib","patentNumber":"10786489","type":"Formulation","expiryDate":"2038-10-10","territory":"US","annualRevenue":700000000,"genericFilings":[]},{"drugName":"Cialis","drugSlug":"tadalafil","patentNumber":"11975006","type":"Formulation","expiryDate":"2038-12-24","territory":"US","genericFilings":[]},{"drugName":"Cialis","drugSlug":"tadalafil","patentNumber":"12186322","type":"Formulation","expiryDate":"2038-12-24","territory":"US","genericFilings":[]},{"drugName":"Cialis","drugSlug":"tadalafil","patentNumber":"11382917","type":"Formulation","expiryDate":"2038-12-24","territory":"US","genericFilings":[]},{"drugName":"Cialis","drugSlug":"tadalafil","patentNumber":"11666576","type":"Formulation","expiryDate":"2038-12-24","territory":"US","genericFilings":[]},{"drugName":"Retevmo","drugSlug":"selpercatinib","patentNumber":"10786489*PED","type":"Compound","expiryDate":"2039-04-10","territory":"US","annualRevenue":700000000,"genericFilings":[]},{"drugName":"Retevmo","drugSlug":"selpercatinib","patentNumber":"10584124*PED","type":"Compound","expiryDate":"2039-04-10","territory":"US","annualRevenue":700000000,"genericFilings":[]},{"drugName":"Mounjaro","drugSlug":"tirzepatide","patentNumber":"11918623","type":"Method of Use","expiryDate":"2039-06-14","territory":"US","annualRevenue":15530000000,"genericFilings":[]},{"drugName":"Mounjaro","drugSlug":"tirzepatide","patentNumber":"12453758","type":"Method of Use","expiryDate":"2039-07-22","territory":"US","annualRevenue":15530000000,"genericFilings":[]}],"drugCount":209,"phaseCounts":{"marketed":94,"phase_1":17,"phase_3":68,"phase_2":29,"discontinued":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}